Premium
Inside Cover: RAFT‐Derived Polymer–Drug Conjugates: Poly(hydroxypropyl methacrylamide) (HPMA)–7‐Ethyl‐10‐hydroxycamptothecin (SN‐38) Conjugates (ChemMedChem 2/2012)
Author(s) -
Williams Charlotte C.,
Thang San H.,
Hantke Tina,
Vogel Uwe,
Seeberger Peter H.,
Tsanaktsidis John,
Lepenies Bernd
Publication year - 2012
Publication title -
chemmedchem
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201290001
Subject(s) - raft , chemistry , conjugate , methacrylamide , polymer , pegylation , peptoid , solubility , combinatorial chemistry , bioavailability , reversible addition−fragmentation chain transfer polymerization , polymerization , polymer chemistry , organic chemistry , copolymer , polyethylene glycol , radical polymerization , peptide , biochemistry , pharmacology , mathematical analysis , acrylamide , mathematics , medicine
The inside cover picture shows how RAFT polymerisation technology can be used to construct well‐ defined drug–polymer conjugates by growing a polymer of desired length, composition and architecture from a specific point of the drug molecule. RAFT is a powerful alternative to PEGylation that provides medicinal chemists with a “second chance” to adjust the solubility and bioavailability of bioactive molecules. For more details, see the Full Paper by J. Tsanaktsidis, B. Lepenies et al. on p. 281 ff.